Given the dependence of skin CD8+ TRM on lipid metabolism and the increasingly uncovered roles of TRM in skin autoimmune diseases such as psoriasis and vitiligo, it is tempting to speculate a novel and promising treatment strategy for skin immune disorders by blocking critical lipid metabolic pathways in TRM. This evidence concerns the gene CD8A and vitiligo.